Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Mario Airoldi et al.|The Lancet|2018Cited by 1.7k
Plasma next generation sequencing and droplet digital PCR‐based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent‐line osimertinibPei Ni Ding, Tara L. Roberts, Therese M. Becker et al.|Thoracic Cancer|2019Cited by 53
The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective studyPei Ni Ding, Tara L. Roberts, Therese M. Becker et al.|Lung Cancer|2019Cited by 41
Pembrolizumab for anaplastic thyroid cancer: a case studyMarra Aghajani, Tara L. Roberts, Adam Cooper et al.|Cancer Immunology Immunotherapy|2019Cited by 30
The Multiple Potential Biomarkers for Predicting Immunotherapy Response—Finding the Needle in the HaystackTamiem Adam, Tara L. Roberts, Therese M. Becker et al.|Cancers|2021Cited by 25